City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Chatchada Karanes, MD  
Search results:  9  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-9 Trials Jump to page:

COH Protocol Number: 16041 ClinicalTrials.gov Number: NCT02701634

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

COH Protocol Number: 15373 ClinicalTrials.gov Number: NCT02283177

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Safety and Tolerability Trial of Crenolanib and Chemotherapy with Cytarabine and Anthracyclines in Patients with Newly Diagnosed Acute Myeloid Leukemia with FLT3 Activating Mutations

COH Protocol Number: 15367 ClinicalTrials.gov Number: NCT02626338

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  Pilot Study of Crenolanib Combined with High-Dose Cytarabine and Mitoxantrone in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 14160 ClinicalTrials.gov Number: NCT01962792

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Multicenter Phase 1/2b Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis™) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 14081

Principal Investigator: Chatchada Karanes, MD
Sponsor: NCI Approved External Peer Review

Title:  Immune Reconstitution after Cord Blood Transplant

COH Protocol Number: 12395 ClinicalTrials.gov Number: NCT01690520

Principal Investigator: Chatchada Karanes, MD
Sponsor: NCI Approved External Peer Review

Title:  Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies (FH2603)

COH Protocol Number: 12331 ClinicalTrials.gov Number: NCT01861093

Principal Investigator: Chatchada Karanes, MD
Sponsor: Institutional

Title:  NYCB 6637: A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

COH Protocol Number: 12086 ClinicalTrials.gov Number: NCT01597778

Principal Investigator: Chatchada Karanes, MD
Sponsor: NCI Approved External Peer Review

Title:  BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies

COH Protocol Number: 11103 ClinicalTrials.gov Number: NCT01351545

Principal Investigator: Chatchada Karanes, MD
Sponsor: Institutional

Title:  CIBMTR 10-CBA: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adults Patients with Hematologic Malignancies and Other Indications

 
Results per page: 25 50 100 All 1-9 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.